Our Vision
To create a healthier world for all people
Our Mission
To discover, develop and deliver innovative therapeutics for people with life-threatening diseases
Our Focus
At Gilead, we strive to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we deliver innovative therapies that offer new hope to those impacted by disease. We invest in world-class science and are pursuing innovation across our therapeutic areas of virology, oncology and inflammation.
Importantly, our focus extends beyond medicine — we take action to help remedy health inequities and break down barriers to care, forming partnerships around the world to bring about change.
We believe that our people are our greatest asset. We empower our employees to bring their whole selves to work and make a direct impact in the communities we serve.
Inspired by our bold ambitions, we're committed to improving the lives of patients and the health of the world for generations to come.
Therapeutic AreasGilead's History
Gilead was founded in 1987 to bring new hope in the face of devastating diseases. For more than 35 years, we've been at the forefront of some of the world's greatest public health challenges.
1987
Our company is founded as Oligogen on
June 22, 1987, and becomes Gilead Sciences one year later.
1990
Gilead's research focus shifts to small molecule therapeutics.
1992
Gilead goes public and $GILD is listed on the Nasdaq stock exchange for the first time.
1996
Gilead’s first medicine is approved for the treatment of cytomegalovirus retinitis in people with AIDS. At the time, Gilead has just 250 employees.
2001
Gilead’s first therapeutic for HIV is approved by the U.S. FDA.
2006
The first single-tablet regimen for HIV, developed by Gilead, is approved by the U.S. FDA, helping transform care for people living with HIV.
2010
Gilead grows to 4,000 employees in 20 countries around the world.
2013
Gilead introduces a new therapeutic advancing a cure for chronic hepatitis C.
2017
Gilead acquires Kite Pharma, entering the cell therapy space. Also, it launches the COMPASS Initiative® to address the HIV epidemic in the Southern U.S.
2019
Gilead expands its reach in communities through the HIV Age Positively program, the HepConnect initiative and RADIAN, and Daniel O’Day is named Chairman and Chief Executive Officer.
2020
Gilead’s COVID-19 antiviral receives U.S. FDA emergency use authorization and the company acquires Immunomedics to accelerate treatments for cancer.
2021
The Gilead Foundation, which was originally established in 2005, was re-endowed.
2022
Gilead acquires MiroBio to accelerate the development of treatment options for people with autoimmune diseases.
2023
Gilead expands by opening a hub in Parsippany, New Jersey to serve as a center for innovation in oncology.
2024
Gilead acquires CymaBay, advancing a transformational therapy for primary biliary cholangitis, and opens its first research lab outside of the U.S. in Oxford, England.